AI assistant
TScan Therapeutics, Inc. — Director's Dealing 2021
Jul 16, 2021
34191_dirs_2021-07-15_2ce05d79-0f26-403f-a67c-7054ef016880.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-07-15
Reporting Person: BARBERICH TIMOTHY J (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $1.97 | 2029-02-04 | Voting Common Stock (27808) | Direct | |
| Stock Option (right to buy) | $2.46 | 2029-12-17 | Voting Common Stock (20082) | Direct | |
| Series B Preferred Stock | $ | Voting Common Stock (33259) | Direct |
Footnotes
F1: The shares subject to this option vest in 48 equal monthly installments following January 24, 2019.
F2: The shares subject to this option vest over 4 years of service following December 5, 2019, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
F3: Each share of the Issuer's Series B Preferred Stock is convertible into shares of the Issuer's Voting Common Stock on a 1 for 1 basis at the holder's election and will automatically convert immediately prior to the closing of the Issuer's initial public offering. These shares have no expiration date.